Street View: Brokerages downgrade Exact Sciences following acquisition by Abbott

Abbott Laboratories

21/11/2025 13:09

**  Cancer test maker Exact Sciences EXAS.O said on Thursday medical device maker Abbott Laboratories ABT.N will acquire the company in a $23 billion deal

** At least five brokerages downgrade the stock

** Median PT of 23 analysts covering stock is $85; average rating is "hold" - data compiled by LSEG

     EXAS SHARES NEAR TAKEOUT PRICE

** Barclays ("equal weight," PT: $105) says it no longer sees big upside as stock is now priced close to what Abbott Laboratories might pay in the acquisition

** Citigroup ("neutral," PT: $105) sees limited upside as the stock is nearing the $105 deal price and is raising their target price to match

** Leerink Partners ("market perform," PT: $105) says the deal marks the first time a central lab or single-site testing company is being bought by a diversified healthcare player, which is bullish for EXAS and the broader diagnostics sector

** Wells Fargo ("equal weight," PT: $105) says the company is expected to close the deal in the second quarter in 2026 and downgrades the stock since it is now trading near the takeout price

 (Reporting by Anuj T in Bengaluru)

 ((anuj.t@thomsonreuters.com))